IDH1 and malignant glioma: Pope et al. [36] also used magnetic resonance spectroscopy (MRS) in patients with glioma to measure the level of the oncometabolite 2-HG which is associated with mutations of IDH1 and IDH2. Patients with IDH1 mutation are more likely to progress to malignant gliomas.